Radiology Research and Practice

Radiology Research and Practice / 2011 / Article

Clinical Study | Open Access

Volume 2011 |Article ID 586785 |

Ying-Hsiang Lee, Yih-Jer Wu, Chuan-Chuan Liu, Charles Jia-Yin Hou, Hung-I. Yeh, Cheng-Ho Tsai, Shou-Chuan Shih, Chung-Lieh Hung, "The Severity of Fatty Liver Disease Relating to Metabolic Abnormalities Independently Predicts Coronary Calcification", Radiology Research and Practice, vol. 2011, Article ID 586785, 8 pages, 2011.

The Severity of Fatty Liver Disease Relating to Metabolic Abnormalities Independently Predicts Coronary Calcification

Academic Editor: Paul E. Kinahan
Received21 Jul 2011
Accepted22 Sep 2011
Published27 Dec 2011


Background. Nonalcoholic fatty liver disease (NAFLD) is one of the metabolic disorders presented in liver. The relationship between severity of NAFLD and coronary atherosclerotic burden remains largely unknown. Methods and Materials. We analyzed subjects undergoing coronary calcium score evaluation by computed tomography (MDCT) and fatty liver assessment using abdominal ultrasonography. Framingham risk score (FRS) and metabolic risk score (MRS) were obtained in all subjects. A graded, semiquantitative score was established to quantify the severity of NAFLD. Multivariate logistic regression analysis was used to depict the association between NAFLD and calcium score. Results. Of all, 342 participants (female: 22.5%, mean age: years) met the sufficient information rendering detailed analysis. The severity of NAFLD was positively associated with MRS ( , trend ) and FRS ( , trend ). After multivariable adjustment for clinical variables and life styles, the existence of moderate to severe NAFLD was independently associated with abnormal calcium score ( ). Conclusion. The severity of NAFLD correlated well with metabolic abnormality and was independently predict coronary calcification beyond clinical factors. Our data suggests that NAFLD based on ultrasonogram could positively reflect the burden of coronary calcification.

1. Introduction

Atherosclerosis is the most common vascular pathology in patients with cardiovascular events, which leads to mortality in developed countries. There are various tools to evaluate the diseased populations for prediction, diagnosis, and risk stratification. Among asymptomatic patients, the predictive and prognostic values of calcium scores via electron beam computed tomography (EBCT) were proved in previous studies, either as an addition to the FRS or to C-reactive protein [1], or used alone [2]. Because coronary calcification is not uncommon in patients with myocardial ischemia, multidetected computed tomography (MDCT) has become a more useful modality for coronary heart disease evaluation. On the other hand, evolving evidence showed that NAFLD may actually represent metabolic syndrome in liver [3]. The existence and severity of NAFLD by liver biopsy as a gold standard also proved to be association with MRS [4, 5]. Recent studies demonstrated that NAFLD could further predict cardiovascular diseases or even involved the pathophysiologic process of atherosclerosis [4].

In our study, we sought to define the correlation between the extent of NAFLD, cardiovascular risks, and MDCT-acquired calcium score. We also tried to examine the role of NAFLD beyond other clinical factors in the prediction and identification of coronary calcification.

2. Materials and Methods

2.1. Study Subjects

We subsequently enrolled 342 non-alcoholism from outpatient clinics or subjects underwent health evaluation who had both MDCT examination for cardiovascular risk stratification as well as abdominal ultrasonography for the detection of fatty liver disease. This study was proved by the ethics committee of Mackay Memorial Hospital, Taipei, Taiwan (09MMHIS038), in accordance with the Declaration of Helsinki.

2.2. Data Collection and Laboratory Parameters

Anthropometric measurements including body height, body weight, waist circumference, and blood pressures at rest were taken by a registered technician who was blinded to the other test results. Body mass index (BMI) was derived from the ratio of weight to height squared. Body surface area (BSA) was calculated according to formula of DuBois. Review of medical history, physical examination, 12-lead electrocardiogram, and chest plain film were all performed by study physicians. High-sensitivity C-reactive protein (hs-CRP) levels were determined by a latex particle-enhanced immunoassay using Elecsys 2010 method (Roche, Mannheim, Germany). The other laboratory data, including a lipid profile and a renal function test, was obtained by a Hitachi 7170 Automatic Analyzer (Hitachi Corp. Hitachinaka Ibaraki, Japan). Immunoreactive insulin was measured by radioimmunoassay (PerkinElmer Automatic Gamma Counter 1470; PerkinElmer, Waltham, MA, USA). Insulin resistance was further defined as using the following homeostasis model equation: insulin resistance method (HOMA-IR) = fasting glucose (mmol/L) × fasting insulin (μU/mL)/22.5. HbA1c level was obtained by high-performance liquid chromatography (Bio-rad Variant II; Bio-Rad Laboratories, Hercules, CA, USA). Body fat composition percentage was assessed by using a commercialized foot-to-foot bioelectrical impedance scale (Tanita Inc., Tokyo, Japan, models TBF 410GS).

2.3. Abdominal Ultrasonography for NAFLD Grading

Abdominal ultrasonography is a validated tool to diagnose fatty liver rather than liver biopsy. The presence of fatty liver disease was detected using abdominal ultrasonography done by an experienced gastroenterologist who has no reference of the participants’ other data. Three levels adopted for evaluating the severity of fatty liver was based on 4 basic techniques (hepatorenal echo contrast, liver brightness, deep attenuation, and vascular blurring) as described from previous studies [6]. Right kidney echogenicity was used for the contrast of liver parenchyma echogenicity. It is normal with the same kidney cortex and liver parenchyma echogenicity. The severity of NAFLD is graded as the following: mild: minimal diffuse increase in liver brightness, but diaphragm and intrahepatic vessel contours seem normal; moderate: medium grade diffuse increase in liver brightness and mild attenuation of diaphragm and intrahepatic vessels; severe: apparent increase in echogenicity. Under the aware that fatty liver interpretation by using ultrasonic assessment may be subjective, we adopted a more strict methodology in categorizing subjects with at least moderate degree fatty liver disease as significant fatty liver disease in this study.

2.4. Coronary Calcium Score Measurement

Coronary calcification of coronary arteries was quantified by using a dedicated offline workstation (Aquarius 3D Workstation, TeraRecon, San Mateo, CA, USA). A coronary calcified lesion was defined as an area with a density >130 HU and covering at least 6 pixels. Scanning was performed by a 16-slice MDCT scanner (Sensation 16, Siemens Medical Solutions, Forchheim, Germany) with  mm  collimation, rotation time 420 ms,  and tube voltage of 120 kV  in one breath hold. From the raw data, the images were reconstructed with standard kernel in 3 mm thick axial, nonoverlapping slices and 25 cm  field of view. The Agatston score method was applied by multiplying each lesion (area) by a weighted CT attenuation score in the lesion.

2.5. Definition of Framingham Risk Score

The Framingham risk score (FRS) is designed to estimate 10-year risk of developing coronary heart disease (myocardial infarction and coronary death) in adults aged 20 and older who do not have heart disease or diabetes. This tool is based on the score (Adult Treatment Panel III, ATP-III) deriving from the information of age, gender, cholesterol dysregulation, (pre) hypertension, and smoking [7].

2.6. Definition of Metabolic Risk Score

Similar to ATP-III criteria, abnormal metabolic components defined by the Bureau of Health Promotion, Department of Health, Taiwan were [8]: (1) increased waist circumference of at least 90 cm  in men and of at least 80 cm  in women; (2) abnormally elevated serum triglycerides (TG) of at least 150 mg /dL; (3) lower serum high-density lipoprotein (HDL) cholesterol of less than 40 mg /dL for men and less than 50 mg /dL for women; (4) higher fasting blood glucose level greater than 110 mg /dL; (5) elevated systolic blood pressure of at least 130 mmHg  and/or diastolic blood pressure of at least 85 mmHg , or undergoing hypertension treatment. The scoring system was calculated and presented as the numbers of abnormal items meeting the criteria, with score 0 for the absence and score 5 for the presence of all 5 abnormal metabolic components. Metabolic risk score (MRS) of 3 or more met the definition of metabolic syndrome.

2.7. Statistics

All data was presented as mean ± SD. Continuous data between groups with and without abnormal calcium score deposition were compared by using Mann-Whitney test with abnormal distribution and by Student t-test if in normal distribution. Categorical variables were compared by Chi square and Fisher Exact tests as appropriate. Nonparametric rank sum test was used to test the graded change of cardiovascular risks estimated by using ATP III or Framingham system over different fatty liver status. Multivariable regression model was used based on Framingham system (FRS) and ATP III (MRS) with life styles or other variables not included in the Framingham system (FRS) or ATP III (MRS) model sequentially entered to identify the independent value in predicting fatty liver disease. Receiving operative characteristic (ROC) curves were used to test the hypothesis that whether the existence of NAFLD helps provide incremental value in the detection of abnormal coronary calcium deposition beyond traditional cardiovascular risk systems. value was set at two-tailed probability, and a value less than 0.05 was considered statistically significant. All analysis was done by the software package STATA 8.2 (StataCorp, College Station, TX, USA).

3. Results

3.1. Patients Demographics and Baseline Characteristics

Of all 342 participants, 239 subjects (mean age 47 years, 27.6% female) did not have notable calcification of all coronary territories (Group I), whereas 103 subjects (mean age 52.6 years, 10% female) were with obvious coronary calcification (Group II). Main demographic data and baseline characteristics are illustrated in Table 1. Subjects with abnormal calcium scores (Group II) were older with more male gender. In addition, they tended to have larger BMI, waist circumference, and higher blood pressure. Baseline biochemistry did not show significant differences between these two groups except a trend toward higher serum glucose level. MRS and FRS were also higher in group II. The prevalence of abnormal electrocardiographic patterns like ischemia or hypertrophy was higher in group II. Subjects in group II were also observed to have higher prevalence of hypertension, diabetes or hyperlipidemia medical history when compared with group I.

 Calcium score zero ( 𝑁 = 2 3 9 )Calcium score abnormal ( 𝑁 = 1 0 3 ) 𝑃 value

Age, years47.0 (6.4)52.6 (6.6)<0.001
Gender, female %66 (27.6)11 (10.6)
Height, cm165.9 (7.5)167.7 (7.5)0.09
Weight, kg65.9 (11.3)68.9 (10.1)0.008
BMI, Kg/m223.8 (3.1)24.4 (2.7)0.013
Waist, cm81.4 (9.1)85.0 (7.9)<0.001
Waist to hip ratio0.88 (0.07)0.91 (0.06)<0.001
SBP, mmHg116.7 (14.9)125.1 (15.1)0.003
DBP, mmHg74.5 (10.2)77.9 (9.7)0.002
 Sugar (AC), mg/dL93.3 (21.2)102.0 (20.9)0.086
 Sugar (PC), mg/dL105.9 (31.6)118.5 (44.4)0.082
 HbA1c, %5.8 (0.6)6.0 (0.6)0.32
 Insulin, U/mL6.25 (4.24)6.91 (3.75)0.046
 HOMA-IR1.55 (1.25)1.76 (1.06)0.016
 Cholesterol, mg/dL191.1 (32.9)196.1 (35.1)0.23
 LDL, mg/dL128.0 (31.3)125.8 (31.7)0.56
 HDL, mg/dL53.0 (13.7)49.1 (12.8)0.02
 TG, mg/dL141.9 (103)145.8 (85.2)0.74
 BUN, mg/dL11.8 (3.2)12.6 (3.7)0.32
 Creatinine, mg/dL0.91 (0.18)0.97 (0.18)0.39
 Uric Acid, mg/dL5.6 (1.4)6.1 (1.5)0.003
 Homocystine, mg/dL7.3 (2.1)8.4 (2.3)0.03
 Hs-CRP, mg/dL0.2 (0.35)0.32 (0.7)0.043
ECG pattern
 ECG (LVH or myocardial ischemia)41 (7.5)28 (13.2)0.016
 ECG (old infarct)5 (1)9 (4.2)0.002
Medical history
 Smoking84 (24.9)42 (29.4)0.311
 HTN history41 (12)35 (23.7)0.001
 DM history11 (3.2)14 (9.5)0.004
 Hyperlipidemia17 (5.6)13 (9.6)0.039
 CVD12 (3.9)12 (8.9)0.033
Family Hx
 Family Hx HTN147 (43)62 (41.9)0.823
 Family Hx DM88 (25.8)42 (28.4)0.554
 Family Hx Stroke49 (14.3)20 (13.5)0.812
 Family Hx CVD57 (16.7)30 (20.3)0.345

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; sugar (AC): fasting glucose; sugar (PC): postprandial glucose; HOMA-IR: insulin resistance; ECG: electrocardiography; LVH: left ventricular hypertrophy; HTN: hypertension; DM: diabetes; NAFLD: nonalcoholic fatty liver disease; CVD: cardiovascular disease: Hx: history.
3.2. The Independent Predictive Value of NAFLD in Different Models

In Figure 1, we illustrated the relationship between coronary calcium score, cardiovascular risk scores, and the degree of fatty liver echogenicity. More severe fatty liver degree was observed to be associated with higher calcium scores, higher FRS and MRS (trend ). We further examined the independent value of NAFLD in the prediction of abnormal coronary calcium scores by testing different clinical variables based on FRS or MRS separately into three different models (Table 2). In model 1, when other clinical variables including smoking and exercise based on the relatively insufficiency of individual scores were entered into regression model, significant fatty liver disease independently identified coronary calcium existence in either FRS group or the MRS group. In model 2, when liver function tests were together in regression model, moderate to severe fatty liver disease was still independently associated in both groups. In model 3, when body fat composition was further entered in the regression model, the presence of fatty liver disease remained statistically significantly independent in the prediction of coronary calcium existence.

VariablesORSE 𝑍 𝑃 CI 95%

Model 1
Sugar (AC)0.990.01−0.50.618.97441721.015514
Fatty liver (moderate to severe)4.472.662.520.0121.39337714.33824
DM history1.922.150.580.563.211482717.35303

Fatty liver (moderate to severe)3.832.132.420.0161.28889711.39297

Model 2
Sugar (AC)0.990.01−0.710.478.97153311.013632
Fatty liver (moderate to severe)7.365.352.750.0061.76990430.56831
DM history1.7120.460.649.171322116.99859
Viral hepatitis carrier1.140.650.230.82.37143423.491325

Fatty liver (moderate to severe)7.434.953.010.0032.01480327.42179
Viral hepatitis carrier1.340.770.510.613.43222224.144012

Model 3
Sugar (AC)0.990.01−0.670.505.97229741.013941
Fatty liver (moderate to severe)6.774.952.620.0091.6144828.35676
DM history1.461.680.330.743.153274313.87366
Viral hepatitis carrier1.310.770.470.641.4185164.118456
Body fat0.920.04−1.940.053.84569791.000979

Fatty liver (moderate to severe)8.5863.070.0022.17602233.82722
Viral hepatitis carrier1.440.840.630.528.46275444.488757
Body fat0.940.04−1.570.117.86795291.015836

FRS: Framingham risk score; MRS: metabolic risk score; γ-GT: γ-glutamyl transpeptidase; GPT: alanine aminotransferase. Other abbreviations were listed in Table 1.
3.3. The Incremental Value of NAFLD beyond Traditional Cardiovascular Risks in the Prediction of Coronary Calcium Scores

In Figure 2, we tested the hypothesis that whether the presence of fatty liver disease could further expand the area under curve (AUC) for the discrimination of coronary artery calcification from normal subjects meaningfully. While FRS and MRS alone have an AUC of 0.67 and 0.64, the addition of NAFLD further significantly expanded the AUC to 0.71 and 0.69, respectively ( -statistics < 0.05).

4. Discussion

In this study, anthropometric data from asymptomatic people without known cardiovascular disease demonstrated a significantly positive correlation between coronary calcium score and traditional anthropometrics, blood pressure, insulin resistance, and systemic inflammation marker in terms of hs-CRP. Both estimated cardiovascular risk scores including FRS and MRS for the prediction of coronary calcification in our study by utilizing ROC analysis were similar to that in Wanamethee’s report [9]. However, unique to this study, we found that more severe fatty liver disease, when assessed by abdominal ultrasonography, may serve as an independent factor even after adjustment of clinical variables and estimated cardiovascular risk scores. Furthermore, we also demonstrated that the presence of more severe degree fatty liver disease added incremental value beyond such traditional cardiovascular risks in the prediction of coronary artery calcification.

Atherosclerosis, conceptualized as a convergence of bone biology with vascular inflammatory pathobiology [10], can recently be assessed and quantified by extent of coronary artery calcification in terms of coronary calcification score when EBCT was clinically introduced and started to serve as a feasible surrogate marker [1113]. Higher calcium scores are seen in most patients with myocardial ischemia, either symptomatic or silent [2, 14]. And the result of coronary calcium score derived from EBCT also predicts stress-related ischemia on stress nuclear images [14] and future cardiovascular events [2].

Metabolic syndrome as a medical disorder complex with a central key factor of obesity accompanied with insulin resistance has been proved as an antecedent of types of diabetes mellitus and several cardiovascular diseases [9, 1520]. Another frequently used cardiovascular risk estimate such as Framingham score is also a widely accepted scoring system, using age, smoking, HDL, BP, and cholesterol instead of triglyceride, in predicting cardiovascular risks [1, 9]. The ATP III had suggested usage of both the metabolic risk factors plus Framingham score in determining the risk of cardiovascular events and targeting treatment goal of LDL. It is thus not surprising that NAFLD, defined as excess fat accumulation in the fat-laden hepatocytes by light microscopy which covers a broad clinical spectrum of liver diseases, be viewed as a component or consequence of metabolic syndrome [21, 22]. However, this “gold standard” is not clinically feasible in daily practice. In the recent years, liver ultrasound has emerged as the most common and simplest one of the alternative tools in NAFLD diagnosis [23].

In contrast to Caucasian, the Asian populations have shown higher prevalence of nonalcoholic steatohepatitis than alcoholic hepatitis with nearly 33% of NAFLD meet the complete diagnosis of metabolic syndrome [24]. In this regard, NAFLD has thus been deemed a hepatic representation of metabolic syndrome [3].

Recent studies have demonstrated that NAFLD patients had developed subclinical atherosclerosis when compared to nonsteatosis individuals. Further, cardiovascular disease is the second most common cause of death in NAFLD patients [4]. More importantly, subjects with known steatosis are associated with abnormal carotid intima-media [25], more vulnerable coronary plaques by MDCT [26], higher serum markers of inflammation [27], worse endothelial function, increased myocardial insulin resistance [28], decreased adiponectin concentrations, and abnormal lipoprotein metabolism [2931].

Ethnic differences in MESA study, such as higher percentage of coronary calcification in Chinese than Hispanic and black groups, was suggestive of unknown mechanism influencing cardiovascular diseases [32]. So far, it remains inconclusive and controversial regarding the true causal relationship between NAFLD and cardiovascular diseases. Some studies had ever described that NAFLD is less likely a direct mediator of cardiovascular disease but an “epiphenomenon" [33]; however, our study reported the independent role of NAFLD in predicting coronary calcification beyond traditional cardiovascular scores. This finding may have an impact on cardiovascular risk stratification or even disease process evaluation. More severe form of NAFLD could thus be viewed as an independent clinical marker for higher cardiovascular risks that may benefit from a more aggressive approach. It also deserves more efforts to work out the influence of liver fat intervention on cardiovascular diseases compared to prior reports [34, 35].

5. Conclusion

The severity of NAFLD not only links to metabolic derangement and traditional cardiovascular risks but also independently identifies the burden of coronary atherosclerosis in terms of coronary calcification. Simple NAFLD grading by liver ultrasonography may serve as a clinically useful tool beyond conventional risk factors in cardiovascular risk stratification.


  1. P. Greenland, L. LaBree, S. P. Azen, T. M. Doherty, and R. C. Detrano, “Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals,” Journal of the American Medical Association, vol. 291, no. 2, pp. 210–215, 2004. View at: Publisher Site | Google Scholar
  2. M. J. Pletcher, J. A. Tice, M. Pignone, and W. S. Browner, “Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis,” Archives of Internal Medicine, vol. 164, no. 12, pp. 1285–1292, 2004. View at: Publisher Site | Google Scholar
  3. A. Kotronen and H. Yki-Järvinen, “Fatty liver: a novel component of the metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 1, pp. 27–38, 2008. View at: Publisher Site | Google Scholar
  4. G. Targher and G. Arcaro, “Non-alcoholic fatty liver disease and increased risk of cardiovascular disease,” Atherosclerosis, vol. 191, no. 2, pp. 235–240, 2007. View at: Publisher Site | Google Scholar
  5. M. C. Ryan, A. M. Wilson, J. Slavin, J. D. Best, A. J. Jenkins, and P. V. Desmond, “Associations between liver histology and severity of the metabolic syndrome in subject with nonalcoholic fatty liver disease,” Diabetes Care, vol. 28, no. 5, pp. 1222–1224, 2005. View at: Publisher Site | Google Scholar
  6. H. Osawa and Y. Mori, “Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes,” Journal of Clinical Ultrasound, vol. 24, no. 1, pp. 25–29, 1996. View at: Publisher Site | Google Scholar
  7. J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at: Google Scholar
  8. C. C. Lin, C. S. Liu, M. M. Lai et al., “Metabolic syndrome in a Taiwanese metropolitan adult population,” BMC Public Health, vol. 7, article 239, 2007. View at: Publisher Site | Google Scholar
  9. S. G. Wannamethee, A. G. Shaper, L. Lennon, and R. W. Morris, “Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus,” Archives of Internal Medicine, vol. 165, no. 22, pp. 2644–2650, 2005. View at: Publisher Site | Google Scholar
  10. T. M. Doherty, K. Asotra, L. A. Fitzpatrick et al., “Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 20, pp. 11201–11206, 2003. View at: Publisher Site | Google Scholar
  11. D. H. Blankenhorn and D. Stern, “Calcification of the coronary arteries,” The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine, vol. 81, no. 5, pp. 772–777, 1959. View at: Google Scholar
  12. G. Sangiorgi, J. A. Rumberger, A. Severson et al., “Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology,” Journal of the American College of Cardiology, vol. 31, no. 1, pp. 126–133, 1998. View at: Publisher Site | Google Scholar
  13. A. S. Agatston, W. R. Janowitz, F. J. Hildner, N. R. Zusmer, M. Viamonte, and R. Detrano, “Quantification of coronary artery calcium using ultrafast computed tomography,” Journal of the American College of Cardiology, vol. 15, no. 4, pp. 827–832, 1990. View at: Google Scholar
  14. Z. X. He, T. D. Hedrick, C. M. Pratt et al., “Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia,” Circulation, vol. 101, no. 3, pp. 244–251, 2000. View at: Google Scholar
  15. S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005. View at: Publisher Site | Google Scholar
  16. S. M. Grundy, “Metabolic syndrome: a multiplex cardiovascular risk factor,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 2, pp. 399–404, 2007. View at: Publisher Site | Google Scholar
  17. B. Isomaa, P. Almgren, T. Tuomi et al., “Cardiovascular morbidity and mortality associated with the metabolic syndrome,” Diabetes Care, vol. 24, no. 4, pp. 683–689, 2001. View at: Google Scholar
  18. Y. Hong, X. Jin, J. Mo et al., “Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality—results of prospective analysis for the Atherosclerosis Risk in Communities study,” Journal of Internal Medicine, vol. 262, no. 1, pp. 113–123, 2007. View at: Publisher Site | Google Scholar
  19. C. A. Daly, P. Hildebrandt, M. Bertrand et al., “Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial,” Heart, vol. 93, no. 11, pp. 1406–1411, 2007. View at: Publisher Site | Google Scholar
  20. S. Malik, N. D. Wong, S. S. Franklin et al., “Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults,” Circulation, vol. 110, no. 10, pp. 1245–1250, 2004. View at: Publisher Site | Google Scholar
  21. B. A. Neuschwander-Tetri and S. H. Caldwell, “Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference,” Hepatology, vol. 37, no. 5, pp. 1202–1219, 2003. View at: Publisher Site | Google Scholar
  22. B. A. Neuschwander-Tetri and S. H. Caldwell, “Nonalcoholic steatohepatitis: summary of an AASLD single topic conference,” Hepatology, vol. 38, no. 2, p. 536, 2003. View at: Google Scholar
  23. M. Karcaaltincaba and O. Akhan, “Imaging of hepatic steatosis and fatty sparing,” European Journal of Radiology, vol. 61, no. 1, pp. 33–43, 2007. View at: Publisher Site | Google Scholar
  24. G. Marchesini, E. Bugianesi, G. Forlani et al., “Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome,” Hepatology, vol. 37, no. 4, pp. 917–923, 2003. View at: Publisher Site | Google Scholar
  25. H. Völzke, D. M. Robinson, V. Kleine et al., “Hepatic steatosis is associated with an increased risk of carotid atherosclerosis,” World Journal of Gastroenterology, vol. 11, no. 12, pp. 1848–1853, 2005. View at: Google Scholar
  26. S. Akabame, M. Hamaguchi, K. I. Tomiyasu et al., “Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT),” Circulation Journal, vol. 72, no. 4, pp. 618–625, 2008. View at: Publisher Site | Google Scholar
  27. J. W. Haukeland, J. K. Damås, Z. Konopski et al., “Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2,” Journal of Hepatology, vol. 44, no. 6, pp. 1167–1174, 2006. View at: Publisher Site | Google Scholar
  28. R. Lautamäki, R. Borra, P. Iozzo et al., “Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes,” American Journal of Physiology—Endocrinology and Metabolism, vol. 291, no. 2, pp. E282–E290, 2006. View at: Publisher Site | Google Scholar
  29. E. Bugianesi, U. Pagotto, R. Manini et al., “Plasma Adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3498–3504, 2005. View at: Publisher Site | Google Scholar
  30. M. Adiels, M. R. Taskinen, C. Packard et al., “Overproduction of large VLDL particles is driven by increased liver fat content in man,” Diabetologia, vol. 49, no. 4, pp. 755–765, 2006. View at: Publisher Site | Google Scholar
  31. N. Chalasani, M. A. Deeg, and D. W. Crabb, “Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 99, no. 8, pp. 1497–1502, 2004. View at: Publisher Site | Google Scholar
  32. D. E. Bild, R. Detrano, D. Peterson et al., “Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA),” Circulation, vol. 111, no. 10, pp. 1313–1320, 2005. View at: Publisher Site | Google Scholar
  33. R. L. McKimmie, K. R. Daniel, J. J. Carr et al., “Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study,” American Journal of Gastroenterology, vol. 103, no. 12, pp. 3029–3035, 2008. View at: Publisher Site | Google Scholar
  34. A. P. M. Viljanen, P. Iozzo, R. Borra et al., “Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, pp. 50–55, 2009. View at: Publisher Site | Google Scholar
  35. J. C. Hannukainen, R. Borra, K. Linderborg et al., “Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity,” Journal of Hepatology, vol. 54, no. 3, pp. 545–552, 2011. View at: Publisher Site | Google Scholar

Copyright © 2011 Ying-Hsiang Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.